John Sullivan, a member of Cozen O’Connor’s Commercial Litigation Department, discusses the second Risperdal trial, Cirba v. Janssen Pharmaceuticals, Inc., in which the trial judge denied the plaintiff’s post-trial motion for a new trial. The trial judge’s denial upheld the jury’s determination that the plaintiffs hadn’t proven that Risperdal caused plaintiff’s medical issues.
To read the article, click here.